LARIAT

October 11, 2016October 11, 2016

First Patient Enrolled in Phase 3 Trial Assessing Bardoxolone Methyl to Treat CTD-PAH

Reata Pharmaceuticals announced the enrollment of the first patient in its Phase 3 CATALYST study (NCT02657356) that will evaluate the effectiveness and safety of bardoxolone methyl in patients with connective ... Read more

January 5, 2016January 6, 2016

LARIAT Clinical Trial Opens to Pulmonary Hypertension Patients with ILD

News, Pulmonary Hypertension

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company based in Irving, Texas, recently announced that it has enrolled the first patient with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in ... Read more

October 27, 2015November 5, 2015

Reata’s PAH Treatment Bardoxolone Methyl Shows Promise in Phase 2 Study

News, Pulmonary Hypertension

Reata Pharmaceuticals has presented the first results of its LARIAT Phase 2 study, a trial assessing the efficacy and safety of experimental therapy bardoxolone methyl in the treatment of pulmonary ... Read more

September 16, 2015November 5, 2015

Reata Announces Presentation of Initial Phase 2 Data on Bardoxolone Methyl for PAH at 2015 CHEST Meeting

News, Pulmonary Hypertension

Irving, Texas-based Reata Pharmaceuticals, Inc, recently announced that it will present initial data evaluating bardoxolone methyl in patients with pulmonary arterial hypertension (PAH) who are on stable background therapy during the 2015 ... Read more

April 15, 2015November 5, 2015

FDA Grants Reata Pharmaceuticals’ Bardoxolone Methyl Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

Reata Pharmaceuticals, Inc., an Irving, Texas-based biopharmaceutical company developing transcription-regulating activity drugs called antioxidant inflammation modulators (AIMs), recently announced that the Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) ... Read more